Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Apr 26, 2023 1:22pm

127 Views

Post# 35414992

RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

I had considered an oral presentation and knew it was a longshot for anyone. Congratulations to all concerned.
We may be looking at 2 AAs, and I do not mean batteries. If that is so, my idea of a pharma collaboration is not so far out.

This would appear to be cutting edge, and I am wondering if anyone can tell me if biomarkers are an integral part of this.

Great work to all concerned.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale